Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function

Next Previous
Search
Trial Profile

A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rucaparib (Primary)
  • Indications Colon cancer; Liver cancer; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Clovis Oncology [CEASED]; pharmaand GmbH

    • Most Recent Events

    • 19 May 2021 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2021 Planned End Date changed from 30 Dec 2020 to 30 Mar 2021.
    • 29 Jul 2020 Planned End Date changed from 30 Jun 2020 to 30 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top